Research programme: gene silencing anticancer therapy - CytoGenixAlternative Names: Gene silencing anticancer therapy research programme - Cytogenix
Latest Information Update: 08 Jun 2010
At a glance
- Originator CytoGenix
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 11 Jan 2005 This compound is still in active development
- 24 Nov 2003 Preclinical trials in Cancer in USA (unspecified route)